Products and Commercial Technologies
2dDR NexGel*
Hydrogel For Diabetic Foot Ulcer
Promotes skin regeneration and wound healing. A bioactive hydrogel designed to maintain a moist wound environment while utilizing 2dDR for angiogenesis in diabetic wounds.
Description
2dDR NexGel is a specialized modification of the NexGel hydrogel dressing. It incorporates 2-deoxy-D-ribose (2dDR), a pro-angiogenic substance that promotes neovascularization and rapid skin regeneration, specifically optimized for the complex environment of diabetic wounds.
Available Sizes
- 10 cm x 10 cm Standard
Advanced Clinical Applications
Diabetic Wounds
Targeted therapy for non-healing diabetic foot ulcers using pro-angiogenic 2dDR technology.
Angiogenesis
Promotes neovascularization to restore blood flow and oxygen to damaged tissue areas.
Chronic Care
Advanced moist-environment healing for pressure ulcers and persistent chronic wounds.
Business Potential
540M+
People worldwide live with diabetes, creating a massive demand for specialized wound care.
$16 Billion
Projected global diabetic wound care market by 2030, with hydrogels leading growth.
$160M+
Estimated annual revenue potential with just 1% global market penetration.
Principal Investigator
Prof. Dr. Muhammad Yar (T.I.)
Professor
Cluster Head, Skin Tissue Engineering Group
IRCBM - CUI Lahore Campus
Strategic Partners
* Cannenta Pty Australia owns license of this technology. MYI to negotiate market access for Pakistan.